Glembatumumab Vedotin provides a glycoprotein NMB (GPNMB)-targeting antibody-drug conjugate (ADC) for cancer and oncology research. Also known as CDX-011, it combines a GPNMB-directed monoclonal antibody with monomethyl auristatin E (MMAE) and specifically supports studies of targeted cytotoxicity, breast cancer, melanoma, and antibody-mediated drug delivery.
Key Features and Benefits
- GPNMB-Targeting ADC: Combines a GPNMB-directed monoclonal antibody with the cytotoxic MMAE payload specifically for targeted cancer research.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule-disrupting agent used in ADC research.
- GPNMB Recognition: Supports investigation of GPNMB expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable valine-citrulline linker specifically designed to facilitate intracellular MMAE release.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to GPNMB-expressing cancer cells.
- Microtubule Disruption: MMAE inhibits microtubule polymerization, specifically supporting studies of cell-cycle arrest and ADC-mediated cytotoxicity.
- CDX-011 Research Platform: Provides an investigational ADC platform specifically for studying GPNMB-directed cancer targeting and payload activity.
Applications
- Triple-Negative Breast Cancer Research: Supports investigation of GPNMB-targeted ADC mechanisms in triple-negative breast cancer models.
- Breast Cancer Research: Useful for studying GPNMB expression and ADC-mediated cytotoxicity in relevant breast cancer models.
- Melanoma Research: Supports investigation of GPNMB-targeted ADC strategies in melanoma models.
- GPNMB-Positive Cancer Research: Useful for studying tumors expressing glycoprotein NMB and associated targeting mechanisms.
- ADC Research: Supports studies of antibody targeting, internalization, payload release, and cytotoxic activity.
- Targeted Cancer Research: Useful for investigating antibody-mediated delivery of MMAE to GPNMB-expressing cancer cells.
- Cell-Based Cancer Assays: Supports evaluation of GPNMB-dependent binding, cellular uptake, and cytotoxic responses.
- Mechanism-of-Action Studies: Supports investigation of GPNMB targeting and MMAE-mediated microtubule disruption.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Glembatumumab Vedotin combines GPNMB-directed antibody targeting with the microtubule-disrupting MMAE payload and specifically supports triple-negative breast cancer, melanoma, GPNMB-positive cancer, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
